Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective

Javier P. Gisbert, Karl Gaffney, David Young, Hans C. Ebbers, Giampiero Girolomoni

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
7 Downloads (Pure)


Introduction: This review provides an overview of data from trials and real-world studies available for SB5 (ImraldiTM) across three main therapeutic areas: rheumatology, gastroenterology, and dermatology. Areas covered: A literature search for publications on data for SB5 efficacy/effectiveness, safety, and immunogenicity was undertaken. Expert opinion: Evidence derived from clinical studies suggest that the biosimilar SB5 is a safe and effective alternative to reference adalimumab. Considering that patients suffering from immune-mediated inflammatory diseases such as inflammatory arthritis, inflammatory bowel disease and psoriasis often require long-term biologic treatment, biosimilar medicines (such as SB5) can reduce healthcare costs while increasing access to effective treatments.

Original languageEnglish
Pages (from-to)109-121
Number of pages13
JournalExpert Opinion on Biological Therapy
Issue number2
Early online date31 Dec 2021
Publication statusPublished - 2022


  • adalimumab
  • anti-TNF
  • Biosimilar
  • dermatology
  • gastroenterology
  • Imraldi®
  • multidisciplinary
  • rheumatology
  • SB5

Cite this